Peter Goodhand is a senior executive and board member in the global health sector. Prior to GA4GH, he was the President and Chief Executive Officer of the Canadian Cancer Society, Canada's largest health charity. Before joining the charitable sector, Goodhand had a 20-year career in the global medical technology industry, including strategic leadership roles with multinational healthcare companies such as American Cyanamid and Johnson & Johnson; Board Chair and President of Canada’s Medical Device Industry association (MEDEC); and as the founding Managing Director and the Board Chair of the Health Technology Exchange (HTX). Goodhand is currently Co-Chair of the International 100K+ Cohorts Consortium (IHCC), Co-Chair of the Medical and Scientific Advisory Board of Global Genes, a member of the Global Genomic Medicine Collaboration (G2MC) Steering Committee, and a member of the Occupational Cancer Research Centre Steering Committee.
The vast majority of available genomic data is from participants that are of white, European ancestry, therefore representing a fraction of the world’s population only. Continued disproportionate advances in genome sciences will exacerbate global healthcare disparities in several ways. This session will address how coordinated, multi-sector solutions could address and preempt such disparities to ensure the promise of precision medicines is realized globally.